Genetically engineered luminescent proteins in biosensing

Laura Rowe, Mark Ensor, Daniel Scott, Sapna K Deo, Sylvia Daunert

Research output: Chapter in Book/Report/Conference proceedingConference contribution

1 Citation (Scopus)

Abstract

Luminescent proteins originally isolated from marine or terrestrial organisms have played a key role in the development of several biosensing systems. These proteins have been used in a variety of applications including, immunoassays, binding assays, cell-based sensing, high throughput screening, optical imaging, etc. Among the luminescent proteins isolated, the bioluminescent protein aequorin has been one of the proteins at the forefront in terms of its use in a vast number of biosensing systems. In our laboratory, we have employed aequorin as a label in the development of highly sensitive assays through chemical and genetic modifications from single step analysis of physiologically important molecules in biological fluids. An important aspect of optimizing these assays for clinical use involves understanding the stability of the various aequorin variants that are available. To this end we have designed several stability studies involving three important aequorin mutants, Mutant S, Mutant 5, and Mutant 53. The cysteine free aequorin, Mutant S, has been the most ubiquitously used aequorin variant in our laboratory because of its increased stability and activity as compared to native aequorin. Mutant 5 and Mutant 53 contain a single cyteine residue at position 5 and 53 in the protein, respectively. Because of the presence of a single cysteine residue, Mutant 5 and Mutant 53 both can be site-specifically conjugated. This site specific conjugation capability gives Mutant 5 and Mutant 53 an advantage over native aequorin when developing assays. Additional studies optimizing the expression, purification, and charging of aequorin Mutant S were also performed. A thorough understanding of the efficient expression, purification, and storage of these aequorin mutants will allow for the more practical utilization of these mutants in the development of future biosensing systems.

Original languageEnglish
Title of host publicationProgress in Biomedical Optics and Imaging - Proceedings of SPIE
Volume6098
DOIs
StatePublished - Jun 26 2006
Externally publishedYes
EventGenetically Engineered Probes for Biomedical Applications - San Jose, CA, United States
Duration: Jan 24 2006Jan 24 2006

Other

OtherGenetically Engineered Probes for Biomedical Applications
CountryUnited States
CitySan Jose, CA
Period1/24/061/24/06

Fingerprint

Proteins
Assays
Purification
Labels
Screening
Throughput
Imaging techniques
Molecules
Fluids

Keywords

  • Aequorin
  • Aequorin expression
  • Bioluminescence
  • Biosensors
  • Luminescent proteins
  • Photoprotein stability
  • Site-directed mutagenesis

ASJC Scopus subject areas

  • Engineering(all)

Cite this

Rowe, L., Ensor, M., Scott, D., Deo, S. K., & Daunert, S. (2006). Genetically engineered luminescent proteins in biosensing. In Progress in Biomedical Optics and Imaging - Proceedings of SPIE (Vol. 6098). [60980H] https://doi.org/10.1117/12.640737

Genetically engineered luminescent proteins in biosensing. / Rowe, Laura; Ensor, Mark; Scott, Daniel; Deo, Sapna K; Daunert, Sylvia.

Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Vol. 6098 2006. 60980H.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Rowe, L, Ensor, M, Scott, D, Deo, SK & Daunert, S 2006, Genetically engineered luminescent proteins in biosensing. in Progress in Biomedical Optics and Imaging - Proceedings of SPIE. vol. 6098, 60980H, Genetically Engineered Probes for Biomedical Applications, San Jose, CA, United States, 1/24/06. https://doi.org/10.1117/12.640737
Rowe L, Ensor M, Scott D, Deo SK, Daunert S. Genetically engineered luminescent proteins in biosensing. In Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Vol. 6098. 2006. 60980H https://doi.org/10.1117/12.640737
Rowe, Laura ; Ensor, Mark ; Scott, Daniel ; Deo, Sapna K ; Daunert, Sylvia. / Genetically engineered luminescent proteins in biosensing. Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Vol. 6098 2006.
@inproceedings{fe1c5a7980f047a79123f712e029ecf0,
title = "Genetically engineered luminescent proteins in biosensing",
abstract = "Luminescent proteins originally isolated from marine or terrestrial organisms have played a key role in the development of several biosensing systems. These proteins have been used in a variety of applications including, immunoassays, binding assays, cell-based sensing, high throughput screening, optical imaging, etc. Among the luminescent proteins isolated, the bioluminescent protein aequorin has been one of the proteins at the forefront in terms of its use in a vast number of biosensing systems. In our laboratory, we have employed aequorin as a label in the development of highly sensitive assays through chemical and genetic modifications from single step analysis of physiologically important molecules in biological fluids. An important aspect of optimizing these assays for clinical use involves understanding the stability of the various aequorin variants that are available. To this end we have designed several stability studies involving three important aequorin mutants, Mutant S, Mutant 5, and Mutant 53. The cysteine free aequorin, Mutant S, has been the most ubiquitously used aequorin variant in our laboratory because of its increased stability and activity as compared to native aequorin. Mutant 5 and Mutant 53 contain a single cyteine residue at position 5 and 53 in the protein, respectively. Because of the presence of a single cysteine residue, Mutant 5 and Mutant 53 both can be site-specifically conjugated. This site specific conjugation capability gives Mutant 5 and Mutant 53 an advantage over native aequorin when developing assays. Additional studies optimizing the expression, purification, and charging of aequorin Mutant S were also performed. A thorough understanding of the efficient expression, purification, and storage of these aequorin mutants will allow for the more practical utilization of these mutants in the development of future biosensing systems.",
keywords = "Aequorin, Aequorin expression, Bioluminescence, Biosensors, Luminescent proteins, Photoprotein stability, Site-directed mutagenesis",
author = "Laura Rowe and Mark Ensor and Daniel Scott and Deo, {Sapna K} and Sylvia Daunert",
year = "2006",
month = "6",
day = "26",
doi = "10.1117/12.640737",
language = "English",
isbn = "0819461407",
volume = "6098",
booktitle = "Progress in Biomedical Optics and Imaging - Proceedings of SPIE",

}

TY - GEN

T1 - Genetically engineered luminescent proteins in biosensing

AU - Rowe, Laura

AU - Ensor, Mark

AU - Scott, Daniel

AU - Deo, Sapna K

AU - Daunert, Sylvia

PY - 2006/6/26

Y1 - 2006/6/26

N2 - Luminescent proteins originally isolated from marine or terrestrial organisms have played a key role in the development of several biosensing systems. These proteins have been used in a variety of applications including, immunoassays, binding assays, cell-based sensing, high throughput screening, optical imaging, etc. Among the luminescent proteins isolated, the bioluminescent protein aequorin has been one of the proteins at the forefront in terms of its use in a vast number of biosensing systems. In our laboratory, we have employed aequorin as a label in the development of highly sensitive assays through chemical and genetic modifications from single step analysis of physiologically important molecules in biological fluids. An important aspect of optimizing these assays for clinical use involves understanding the stability of the various aequorin variants that are available. To this end we have designed several stability studies involving three important aequorin mutants, Mutant S, Mutant 5, and Mutant 53. The cysteine free aequorin, Mutant S, has been the most ubiquitously used aequorin variant in our laboratory because of its increased stability and activity as compared to native aequorin. Mutant 5 and Mutant 53 contain a single cyteine residue at position 5 and 53 in the protein, respectively. Because of the presence of a single cysteine residue, Mutant 5 and Mutant 53 both can be site-specifically conjugated. This site specific conjugation capability gives Mutant 5 and Mutant 53 an advantage over native aequorin when developing assays. Additional studies optimizing the expression, purification, and charging of aequorin Mutant S were also performed. A thorough understanding of the efficient expression, purification, and storage of these aequorin mutants will allow for the more practical utilization of these mutants in the development of future biosensing systems.

AB - Luminescent proteins originally isolated from marine or terrestrial organisms have played a key role in the development of several biosensing systems. These proteins have been used in a variety of applications including, immunoassays, binding assays, cell-based sensing, high throughput screening, optical imaging, etc. Among the luminescent proteins isolated, the bioluminescent protein aequorin has been one of the proteins at the forefront in terms of its use in a vast number of biosensing systems. In our laboratory, we have employed aequorin as a label in the development of highly sensitive assays through chemical and genetic modifications from single step analysis of physiologically important molecules in biological fluids. An important aspect of optimizing these assays for clinical use involves understanding the stability of the various aequorin variants that are available. To this end we have designed several stability studies involving three important aequorin mutants, Mutant S, Mutant 5, and Mutant 53. The cysteine free aequorin, Mutant S, has been the most ubiquitously used aequorin variant in our laboratory because of its increased stability and activity as compared to native aequorin. Mutant 5 and Mutant 53 contain a single cyteine residue at position 5 and 53 in the protein, respectively. Because of the presence of a single cysteine residue, Mutant 5 and Mutant 53 both can be site-specifically conjugated. This site specific conjugation capability gives Mutant 5 and Mutant 53 an advantage over native aequorin when developing assays. Additional studies optimizing the expression, purification, and charging of aequorin Mutant S were also performed. A thorough understanding of the efficient expression, purification, and storage of these aequorin mutants will allow for the more practical utilization of these mutants in the development of future biosensing systems.

KW - Aequorin

KW - Aequorin expression

KW - Bioluminescence

KW - Biosensors

KW - Luminescent proteins

KW - Photoprotein stability

KW - Site-directed mutagenesis

UR - http://www.scopus.com/inward/record.url?scp=33745215144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745215144&partnerID=8YFLogxK

U2 - 10.1117/12.640737

DO - 10.1117/12.640737

M3 - Conference contribution

SN - 0819461407

SN - 9780819461407

VL - 6098

BT - Progress in Biomedical Optics and Imaging - Proceedings of SPIE

ER -